Marijn Verhoef to moderate industry panel on expanding access to monoclonal antibodies via public-private partnerships

Marijn will be moderating an industry panel discussion on “Lessons learned and key considerations for participation in public-private partnership models to commercialise priority products in low- and middle-income countries (LMICs)” as part of a two-day consultation convened by IAVI, Unitaid and the Medicines Patent Pool.

As the moderator, Marijn will facilitate discussions with expert panelists on key issues aimed at generating momentum and identifying innovative partnership strategies for sustainable, affordable business models to provide access to monoclonal antibodies (mAbs) in LMICs. MAbs are laboratory-made proteins that act like human antibodies and are used to treat various diseases, including certain types of cancer and infectious diseases.

Among other issues, the discussion will focus on viable and sustainable business model approaches, as well as priority interventions and enablers – such as licensing, market-shaping and de-risking incentives – that can catalyse access to medicine.

Key topics:

• Opportunities and challenges regarding access to mAbs.

• Enablers and key incentives to support participation in novel business collaborations.

• Lessons learned from past partnership/novel business models for global health products.

Panelists:

• Ariane McCabe, Lead Global Health Policy & Advocacy and Geneva Advocacy at GSK

• Mauricio Zuma Medeiros, CEO of Bio-Manguinhos

• Nigel Shipston, Senior Director, Business Development at Just-Evotec Biologics

• Patrick Tippoo, Head of Science and Innovation at Biovac and Executive Director at the African Vaccine Manufacturing Initiative (AVMI)

• Rajesh Gupta, VP Global Health Portfolio and Public-Private Partnerships at Vir